Table 1.
Clinicopathological features of 1,368 lung adenocarcinoma patients
| Variables | KRAS | EGFR | HER2 | BRAF | ALK/RET/ROS1 | WT and others |
|---|---|---|---|---|---|---|
| Mutation type, n (%) | 113 (8.26) | 837 (61.18) | 32 (2.34) | 20 (1.46) | 102 (7.46) | 264 (19.30) |
| Age, years | ||||||
| <60, n (%) | 63 (56) | 414 (49) | 23 (72) | 11 (55) | 64 (73) | 116 (44) |
| ≥60, n (%) | 50 (44) | 423 (51) | 9 (28) | 9 (45) | 38 (27) | 148 (56) |
| Mean | 59.46 | 59.95 | 54.43 | 57.76 | 56.66 | 60.87 |
| Standard deviation | 9.04 | 9.96 | 9.85 | 9.47 | 9.81 | 10.72 |
| Sex | ||||||
| Male, n (%) | 90 (80) | 303 (36) | 2 (6) | 12 (60) | 39 (6) | 177 (67) |
| Female, n (%) | 23 (20) | 534 (64) | 30 (94) | 8 (40) | 63 (94) | 87 (33) |
| Smoker | ||||||
| Never, n (%) | 34 (30) | 657 (78) | 32 (100) | 8 (40) | 75 (100) | 114 (43) |
| Current/former, n (%) | 79 (70) | 180 (22) | 0 (−) | 12 (60) | 27 (−) | 150 (57) |
| Differentiation | ||||||
| Well, n (%) | 11 (10) | 131 (16) | 9 (28) | 4 (20) | 7 (27) | 30 (11) |
| Moderate, n (%) | 52 (46) | 494 (59) | 14 (44) | 8 (40) | 55 (46) | 102 (39) |
| Poor, n (%) | 50 (44) | 212 (25) | 9 (28) | 8 (40) | 40 (27) | 132 (50) |
| Pathological stage | ||||||
| I, n (%) | 56 (50) | 496 (59) | 20 (63) | 11 (55) | 39 (61) | 127 (48) |
| II, n (%) | 22 (19) | 90 (11) | 1 (3) | 2 (10) | 16 (3) | 36 (14) |
| III, n (%) | 33 (29) | 235 (28) | 11 (34) | 7 (35) | 42 (33) | 97 (37) |
| IV, n (%) | 2 (2) | 16 (2) | 0 (−) | 0 (−) | 5 (3) | 4 (2) |
| Pathological subtype | ||||||
| AIS, n (%) | 0 (−) | 15 (1.8) | 3 (9.4) | 0 (−) | 1 (1.0) | 9 (3.4) |
| MIA, n (%) | 2 (1.8) | 25 (3.0) | 2 (6.3) | 0 (−) | 0 (−) | 4 (1.5) |
| Lepidic, n (%) | 5 (4.4) | 92 (11.0) | 1 (3.1) | 3 (15.0) | 3 (2.9) | 17 (6.4) |
| Acinar, n (%) | 34 (30.1) | 430 (51.4) | 13 (40.6) | 5 (25.0) | 28 (27.5) | 79 (30.0) |
| Papillary, n (%) | 14 (12.4) | 139 (16.6) | 4 (12.5) | 3 (15.0) | 18 (17.6) | 35 (13.3) |
| Micropapillary, n (%) | 0 (−) | 18 (2.2) | 0 (−) | 0 (−) | 1 (1.0) | 2 (0.8) |
| Solid, n (%) | 34 (30.1) | 90 (10.8) | 4 (12.5) | 5 (25.0) | 30 (29.4) | 91 (34.5) |
| IMA, n (%) | 23 (20.4) | 18 (2.2) | 5 (15.6) | 2 (10.0) | 19 (18.6) | 15 (5.7) |
| Other, n (%) | 1 (0.9) | 10 (1.2) | 0 (−) | 2 (10.0) | 2 (2.0) | 12 (4.5) |
Note: Other includes enteric subtype and unknown.
Abbreviations: AIS, adenocarcinoma in situ; IMA, invasive mucinous adenocarcinoma; MIA, minimally invasive adenocarcinoma; WT, wild type.